dr vos quits, page-5

needle-

If there's no trading halt on Monday or Tuesday, we may well see 16 cents in the rear view mirror in advance of the announcement, which I feel has to come fairly soon.

I was unaware that Dr. Vos had traveled to Australia to announce his resignation. If he did indeed do that, then there is even less reason to think that his leaving has a negative connotation of some kind, and more reason to think that it was a decision based on other factors entirely, as I suggested earlier might be the case.

Apropos of your remark that some feedback regarding the progress of the trial must have come back to MBP months ago, I tend to agree. After all, if a pain drug works as well as we all hope this one does, the patient is going to tell the Doctor on the spot. I credit the company for keeping the lid on this as well as they have.

Another factor to consider is that when they had faairly conclusive results showing that AOD9604 wasn't going to be a commercially successful weight loss drug, they wasted no time getting the news out, but there has been no hurry here.

Moreover, it is my conjecture that ACV1 has the potential to elicit a far higher degree of interest by Big Pharma than did AOD9604. It is not impossible that a potential deal could already be in the works conditioned on the outcome of this trial.

In 2002 Neuromed cut a deal with Merck worth $400 to $500 million for a drug that seems to have no better prospects than ACV1.

I know that it's not a good investment strategy to put all ones eggs in one basket, but I think it's also a mistake to over diversify. I don't hold many different shares, and the're not all in biotech. I have had mixed success - not all my calls have worked out.

I think this one is going to make up for all my past mistakes.